nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—FGFR3—colon cancer	0.45	0.906	CbGaD
Pazopanib—ABCB1—colon cancer	0.0465	0.0936	CbGaD
Pazopanib—UGT1A1—Irinotecan—colon cancer	0.0395	0.196	CbGbCtD
Pazopanib—SLCO1B1—Irinotecan—colon cancer	0.0274	0.136	CbGbCtD
Pazopanib—ABCG2—Irinotecan—colon cancer	0.0217	0.108	CbGbCtD
Pazopanib—ABCG2—Fluorouracil—colon cancer	0.0209	0.103	CbGbCtD
Pazopanib—ABCG2—Vincristine—colon cancer	0.019	0.0941	CbGbCtD
Pazopanib—SLCO1B1—Methotrexate—colon cancer	0.0145	0.0717	CbGbCtD
Pazopanib—ABCG2—Methotrexate—colon cancer	0.0115	0.057	CbGbCtD
Pazopanib—CYP2C8—Fluorouracil—colon cancer	0.0111	0.0551	CbGbCtD
Pazopanib—CYP1A2—Fluorouracil—colon cancer	0.0086	0.0426	CbGbCtD
Pazopanib—ABCB1—Irinotecan—colon cancer	0.00784	0.0388	CbGbCtD
Pazopanib—ABCB1—Vincristine—colon cancer	0.00685	0.0339	CbGbCtD
Pazopanib—CYP3A4—Irinotecan—colon cancer	0.0047	0.0233	CbGbCtD
Pazopanib—ABCB1—Methotrexate—colon cancer	0.00415	0.0206	CbGbCtD
Pazopanib—CYP3A4—Vincristine—colon cancer	0.0041	0.0203	CbGbCtD
Pazopanib—KIT—myenteric nerve plexus—colon cancer	0.00324	0.0381	CbGeAlD
Pazopanib—PLK4—Topotecan—Irinotecan—colon cancer	0.00209	1	CbGdCrCtD
Pazopanib—FLT1—umbilical vein—colon cancer	0.00202	0.0238	CbGeAlD
Pazopanib—KDR—umbilical vein—colon cancer	0.00171	0.0201	CbGeAlD
Pazopanib—FLT4—endothelium—colon cancer	0.00123	0.0145	CbGeAlD
Pazopanib—MAP3K9—epithelium—colon cancer	0.0012	0.0141	CbGeAlD
Pazopanib—FLT4—blood vessel—colon cancer	0.00114	0.0134	CbGeAlD
Pazopanib—FGF1—endothelium—colon cancer	0.0011	0.0129	CbGeAlD
Pazopanib—Rilpivirine—ABCB1—colon cancer	0.00108	1	CrCbGaD
Pazopanib—FGF1—blood vessel—colon cancer	0.00101	0.0119	CbGeAlD
Pazopanib—FLT1—endothelium—colon cancer	0.00096	0.0113	CbGeAlD
Pazopanib—MAP3K9—digestive system—colon cancer	0.000913	0.0107	CbGeAlD
Pazopanib—FLT1—blood vessel—colon cancer	0.000885	0.0104	CbGeAlD
Pazopanib—FGFR3—embryo—colon cancer	0.00087	0.0102	CbGeAlD
Pazopanib—TAOK1—renal system—colon cancer	0.000836	0.00983	CbGeAlD
Pazopanib—KDR—endothelium—colon cancer	0.000811	0.00954	CbGeAlD
Pazopanib—MAP3K9—vagina—colon cancer	0.000806	0.00948	CbGeAlD
Pazopanib—PDGFRA—gall bladder—colon cancer	0.00078	0.00918	CbGeAlD
Pazopanib—ITK—lymphoid tissue—colon cancer	0.000762	0.00897	CbGeAlD
Pazopanib—KDR—blood vessel—colon cancer	0.000748	0.0088	CbGeAlD
Pazopanib—KIT—endothelium—colon cancer	0.000719	0.00846	CbGeAlD
Pazopanib—FGFR3—epithelium—colon cancer	0.00071	0.00835	CbGeAlD
Pazopanib—BMPR1B—epithelium—colon cancer	0.000703	0.00827	CbGeAlD
Pazopanib—ITK—bone marrow—colon cancer	0.000694	0.00816	CbGeAlD
Pazopanib—MAP3K9—liver—colon cancer	0.00068	0.008	CbGeAlD
Pazopanib—FLT4—embryo—colon cancer	0.000679	0.00799	CbGeAlD
Pazopanib—ITK—vagina—colon cancer	0.000665	0.00782	CbGeAlD
Pazopanib—KIT—blood vessel—colon cancer	0.000663	0.0078	CbGeAlD
Pazopanib—FGFR3—renal system—colon cancer	0.000659	0.00775	CbGeAlD
Pazopanib—SH2B3—lymphoid tissue—colon cancer	0.000653	0.00768	CbGeAlD
Pazopanib—PDGFRB—blood vessel—colon cancer	0.000648	0.00762	CbGeAlD
Pazopanib—TAOK1—bone marrow—colon cancer	0.000632	0.00743	CbGeAlD
Pazopanib—KIT—gall bladder—colon cancer	0.000624	0.00734	CbGeAlD
Pazopanib—PDGFRB—gall bladder—colon cancer	0.000609	0.00717	CbGeAlD
Pazopanib—TAOK1—vagina—colon cancer	0.000605	0.00712	CbGeAlD
Pazopanib—PI4KB—smooth muscle tissue—colon cancer	0.000605	0.00712	CbGeAlD
Pazopanib—FGF1—embryo—colon cancer	0.000603	0.00709	CbGeAlD
Pazopanib—SH2B3—bone marrow—colon cancer	0.000595	0.007	CbGeAlD
Pazopanib—PLK4—lymphoid tissue—colon cancer	0.000588	0.00692	CbGeAlD
Pazopanib—PI4KB—renal system—colon cancer	0.000583	0.00685	CbGeAlD
Pazopanib—SH2B3—vagina—colon cancer	0.00057	0.0067	CbGeAlD
Pazopanib—FGFR2—embryo—colon cancer	0.00057	0.0067	CbGeAlD
Pazopanib—STK16—lymphoid tissue—colon cancer	0.000556	0.00653	CbGeAlD
Pazopanib—FLT4—epithelium—colon cancer	0.000554	0.00652	CbGeAlD
Pazopanib—LYN—lymphoid tissue—colon cancer	0.00055	0.00647	CbGeAlD
Pazopanib—STK16—digestive system—colon cancer	0.000549	0.00645	CbGeAlD
Pazopanib—PLK4—bone marrow—colon cancer	0.000536	0.0063	CbGeAlD
Pazopanib—FLT1—embryo—colon cancer	0.000528	0.00621	CbGeAlD
Pazopanib—MAP3K9—lymph node—colon cancer	0.000522	0.00613	CbGeAlD
Pazopanib—TAOK1—liver—colon cancer	0.000511	0.00601	CbGeAlD
Pazopanib—RIOK2—bone marrow—colon cancer	0.000498	0.00586	CbGeAlD
Pazopanib—PDGFRA—embryo—colon cancer	0.000495	0.00582	CbGeAlD
Pazopanib—FGF1—epithelium—colon cancer	0.000492	0.00579	CbGeAlD
Pazopanib—STK16—vagina—colon cancer	0.000485	0.0057	CbGeAlD
Pazopanib—SH2B3—liver—colon cancer	0.000481	0.00565	CbGeAlD
Pazopanib—RIOK2—vagina—colon cancer	0.000477	0.00561	CbGeAlD
Pazopanib—LIMK2—lymphoid tissue—colon cancer	0.000475	0.00559	CbGeAlD
Pazopanib—FGF1—smooth muscle tissue—colon cancer	0.000474	0.00558	CbGeAlD
Pazopanib—FGFR2—epithelium—colon cancer	0.000465	0.00547	CbGeAlD
Pazopanib—FGF1—renal system—colon cancer	0.000457	0.00537	CbGeAlD
Pazopanib—FGFR2—smooth muscle tissue—colon cancer	0.000448	0.00527	CbGeAlD
Pazopanib—KDR—embryo—colon cancer	0.000446	0.00525	CbGeAlD
Pazopanib—PI4KB—bone marrow—colon cancer	0.000441	0.00518	CbGeAlD
Pazopanib—CSF1R—embryo—colon cancer	0.000436	0.00512	CbGeAlD
Pazopanib—FGFR2—renal system—colon cancer	0.000431	0.00507	CbGeAlD
Pazopanib—FLT1—epithelium—colon cancer	0.000431	0.00507	CbGeAlD
Pazopanib—ITK—lymph node—colon cancer	0.00043	0.00506	CbGeAlD
Pazopanib—STK36—vagina—colon cancer	0.000429	0.00504	CbGeAlD
Pazopanib—FLT4—lymphoid tissue—colon cancer	0.000427	0.00502	CbGeAlD
Pazopanib—PI4KB—vagina—colon cancer	0.000422	0.00496	CbGeAlD
Pazopanib—FLT1—smooth muscle tissue—colon cancer	0.000415	0.00488	CbGeAlD
Pazopanib—LIMK2—vagina—colon cancer	0.000414	0.00487	CbGeAlD
Pazopanib—STK16—liver—colon cancer	0.000409	0.00481	CbGeAlD
Pazopanib—LYN—liver—colon cancer	0.000405	0.00476	CbGeAlD
Pazopanib—RIOK2—liver—colon cancer	0.000402	0.00473	CbGeAlD
Pazopanib—FGFR3—liver—colon cancer	0.000402	0.00473	CbGeAlD
Pazopanib—MAP3K2—lymphoid tissue—colon cancer	0.000402	0.00473	CbGeAlD
Pazopanib—FLT1—renal system—colon cancer	0.0004	0.0047	CbGeAlD
Pazopanib—KIT—embryo—colon cancer	0.000396	0.00465	CbGeAlD
Pazopanib—TAOK1—lymph node—colon cancer	0.000392	0.00461	CbGeAlD
Pazopanib—PDGFRA—smooth muscle tissue—colon cancer	0.000389	0.00458	CbGeAlD
Pazopanib—FLT4—bone marrow—colon cancer	0.000389	0.00457	CbGeAlD
Pazopanib—PIP4K2C—bone marrow—colon cancer	0.000386	0.00455	CbGeAlD
Pazopanib—PDGFRB—embryo—colon cancer	0.000386	0.00454	CbGeAlD
Pazopanib—FGF1—lymphoid tissue—colon cancer	0.000379	0.00446	CbGeAlD
Pazopanib—STK10—renal system—colon cancer	0.000378	0.00445	CbGeAlD
Pazopanib—TAOK3—renal system—colon cancer	0.000377	0.00443	CbGeAlD
Pazopanib—PDGFRA—renal system—colon cancer	0.000374	0.0044	CbGeAlD
Pazopanib—FGF1—digestive system—colon cancer	0.000374	0.0044	CbGeAlD
Pazopanib—PIP4K2C—vagina—colon cancer	0.00037	0.00435	CbGeAlD
Pazopanib—SH2B3—lymph node—colon cancer	0.000369	0.00434	CbGeAlD
Pazopanib—FGFR1—vagina—colon cancer	0.000367	0.00432	CbGeAlD
Pazopanib—MAP3K2—bone marrow—colon cancer	0.000366	0.00431	CbGeAlD
Pazopanib—KDR—epithelium—colon cancer	0.000364	0.00428	CbGeAlD
Pazopanib—AURKC—lymph node—colon cancer	0.000363	0.00427	CbGeAlD
Pazopanib—STK36—liver—colon cancer	0.000362	0.00425	CbGeAlD
Pazopanib—UGT1A1—renal system—colon cancer	0.000357	0.0042	CbGeAlD
Pazopanib—PI4KB—liver—colon cancer	0.000356	0.00419	CbGeAlD
Pazopanib—FGFR2—digestive system—colon cancer	0.000354	0.00416	CbGeAlD
Pazopanib—KDR—smooth muscle tissue—colon cancer	0.000351	0.00413	CbGeAlD
Pazopanib—LIMK2—liver—colon cancer	0.00035	0.00411	CbGeAlD
Pazopanib—LCK—bone marrow—colon cancer	0.000343	0.00403	CbGeAlD
Pazopanib—CSF1R—smooth muscle tissue—colon cancer	0.000343	0.00403	CbGeAlD
Pazopanib—KDR—renal system—colon cancer	0.000338	0.00397	CbGeAlD
Pazopanib—PLK4—lymph node—colon cancer	0.000332	0.0039	CbGeAlD
Pazopanib—FLT1—lymphoid tissue—colon cancer	0.000332	0.0039	CbGeAlD
Pazopanib—LCK—vagina—colon cancer	0.000329	0.00387	CbGeAlD
Pazopanib—FLT1—digestive system—colon cancer	0.000328	0.00386	CbGeAlD
Pazopanib—KIT—epithelium—colon cancer	0.000323	0.0038	CbGeAlD
Pazopanib—PDGFRB—epithelium—colon cancer	0.000315	0.00371	CbGeAlD
Pazopanib—STK10—lymphoid tissue—colon cancer	0.000314	0.00369	CbGeAlD
Pazopanib—FLT4—liver—colon cancer	0.000314	0.00369	CbGeAlD
Pazopanib—STK16—lymph node—colon cancer	0.000313	0.00369	CbGeAlD
Pazopanib—TAOK3—lymphoid tissue—colon cancer	0.000313	0.00368	CbGeAlD
Pazopanib—PIP4K2C—liver—colon cancer	0.000312	0.00367	CbGeAlD
Pazopanib—KIT—smooth muscle tissue—colon cancer	0.000311	0.00366	CbGeAlD
Pazopanib—PDGFRA—lymphoid tissue—colon cancer	0.000311	0.00366	CbGeAlD
Pazopanib—STK10—digestive system—colon cancer	0.00031	0.00365	CbGeAlD
Pazopanib—FGFR1—liver—colon cancer	0.00031	0.00364	CbGeAlD
Pazopanib—TAOK3—digestive system—colon cancer	0.000309	0.00364	CbGeAlD
Pazopanib—RIOK2—lymph node—colon cancer	0.000309	0.00363	CbGeAlD
Pazopanib—PDGFRA—digestive system—colon cancer	0.000307	0.00361	CbGeAlD
Pazopanib—BMPR1B—lymph node—colon cancer	0.000305	0.00359	CbGeAlD
Pazopanib—PDGFRB—smooth muscle tissue—colon cancer	0.000304	0.00357	CbGeAlD
Pazopanib—KIT—renal system—colon cancer	0.000299	0.00352	CbGeAlD
Pazopanib—SLCO1B1—renal system—colon cancer	0.000297	0.0035	CbGeAlD
Pazopanib—MAP3K2—liver—colon cancer	0.000296	0.00348	CbGeAlD
Pazopanib—UGT1A1—digestive system—colon cancer	0.000293	0.00345	CbGeAlD
Pazopanib—PDGFRB—renal system—colon cancer	0.000292	0.00344	CbGeAlD
Pazopanib—FLT1—vagina—colon cancer	0.000289	0.0034	CbGeAlD
Pazopanib—EPHB6—vagina—colon cancer	0.000286	0.00337	CbGeAlD
Pazopanib—STK10—bone marrow—colon cancer	0.000286	0.00336	CbGeAlD
Pazopanib—TAOK3—bone marrow—colon cancer	0.000285	0.00335	CbGeAlD
Pazopanib—KDR—lymphoid tissue—colon cancer	0.000281	0.0033	CbGeAlD
Pazopanib—FGF1—liver—colon cancer	0.000279	0.00328	CbGeAlD
Pazopanib—LCK—liver—colon cancer	0.000277	0.00326	CbGeAlD
Pazopanib—STK36—lymph node—colon cancer	0.000277	0.00326	CbGeAlD
Pazopanib—KDR—digestive system—colon cancer	0.000277	0.00326	CbGeAlD
Pazopanib—STK10—vagina—colon cancer	0.000274	0.00322	CbGeAlD
Pazopanib—CSF1R—lymphoid tissue—colon cancer	0.000274	0.00322	CbGeAlD
Pazopanib—TAOK3—vagina—colon cancer	0.000273	0.00321	CbGeAlD
Pazopanib—PI4KB—lymph node—colon cancer	0.000273	0.00321	CbGeAlD
Pazopanib—PDGFRA—vagina—colon cancer	0.000271	0.00319	CbGeAlD
Pazopanib—CSF1R—digestive system—colon cancer	0.00027	0.00318	CbGeAlD
Pazopanib—LIMK2—lymph node—colon cancer	0.000268	0.00315	CbGeAlD
Pazopanib—FGFR2—liver—colon cancer	0.000263	0.0031	CbGeAlD
Pazopanib—KDR—bone marrow—colon cancer	0.000255	0.003	CbGeAlD
Pazopanib—CSF1R—bone marrow—colon cancer	0.000249	0.00293	CbGeAlD
Pazopanib—KIT—lymphoid tissue—colon cancer	0.000249	0.00292	CbGeAlD
Pazopanib—KIT—digestive system—colon cancer	0.000246	0.00289	CbGeAlD
Pazopanib—KDR—vagina—colon cancer	0.000245	0.00288	CbGeAlD
Pazopanib—MAP2K5—vagina—colon cancer	0.000245	0.00288	CbGeAlD
Pazopanib—FLT1—liver—colon cancer	0.000244	0.00287	CbGeAlD
Pazopanib—SLCO1B1—digestive system—colon cancer	0.000244	0.00287	CbGeAlD
Pazopanib—PDGFRB—lymphoid tissue—colon cancer	0.000243	0.00286	CbGeAlD
Pazopanib—FLT4—lymph node—colon cancer	0.000241	0.00283	CbGeAlD
Pazopanib—PDGFRB—digestive system—colon cancer	0.00024	0.00282	CbGeAlD
Pazopanib—PIP4K2C—lymph node—colon cancer	0.000239	0.00282	CbGeAlD
Pazopanib—CSF1R—vagina—colon cancer	0.000239	0.00281	CbGeAlD
Pazopanib—FGFR1—lymph node—colon cancer	0.000238	0.00279	CbGeAlD
Pazopanib—STK10—liver—colon cancer	0.000231	0.00272	CbGeAlD
Pazopanib—TAOK3—liver—colon cancer	0.00023	0.00271	CbGeAlD
Pazopanib—PDGFRA—liver—colon cancer	0.000229	0.00269	CbGeAlD
Pazopanib—MAP3K2—lymph node—colon cancer	0.000227	0.00267	CbGeAlD
Pazopanib—KIT—bone marrow—colon cancer	0.000226	0.00266	CbGeAlD
Pazopanib—PDGFRB—bone marrow—colon cancer	0.000221	0.0026	CbGeAlD
Pazopanib—UGT1A1—liver—colon cancer	0.000218	0.00257	CbGeAlD
Pazopanib—KIT—vagina—colon cancer	0.000217	0.00255	CbGeAlD
Pazopanib—FGF1—lymph node—colon cancer	0.000214	0.00252	CbGeAlD
Pazopanib—LCK—lymph node—colon cancer	0.000213	0.0025	CbGeAlD
Pazopanib—PDGFRB—vagina—colon cancer	0.000212	0.00249	CbGeAlD
Pazopanib—KDR—liver—colon cancer	0.000206	0.00243	CbGeAlD
Pazopanib—MAP2K5—liver—colon cancer	0.000206	0.00243	CbGeAlD
Pazopanib—CSF1R—liver—colon cancer	0.000201	0.00237	CbGeAlD
Pazopanib—FLT1—lymph node—colon cancer	0.000187	0.0022	CbGeAlD
Pazopanib—EPHB6—lymph node—colon cancer	0.000185	0.00218	CbGeAlD
Pazopanib—KIT—liver—colon cancer	0.000183	0.00215	CbGeAlD
Pazopanib—SLCO1B1—liver—colon cancer	0.000182	0.00214	CbGeAlD
Pazopanib—ABCB1—blood vessel—colon cancer	0.000179	0.00211	CbGeAlD
Pazopanib—PDGFRB—liver—colon cancer	0.000179	0.0021	CbGeAlD
Pazopanib—Hypoaesthesia—Fluorouracil—colon cancer	0.000178	0.00191	CcSEcCtD
Pazopanib—STK10—lymph node—colon cancer	0.000177	0.00208	CbGeAlD
Pazopanib—Skin exfoliation—Methotrexate—colon cancer	0.000177	0.00189	CcSEcCtD
Pazopanib—TAOK3—lymph node—colon cancer	0.000177	0.00208	CbGeAlD
Pazopanib—PDGFRA—lymph node—colon cancer	0.000175	0.00206	CbGeAlD
Pazopanib—Face oedema—Capecitabine—colon cancer	0.000175	0.00187	CcSEcCtD
Pazopanib—Angiopathy—Vincristine—colon cancer	0.000174	0.00186	CcSEcCtD
Pazopanib—Cardiac disorder—Irinotecan—colon cancer	0.000174	0.00186	CcSEcCtD
Pazopanib—Flushing—Irinotecan—colon cancer	0.000174	0.00186	CcSEcCtD
Pazopanib—Mediastinal disorder—Vincristine—colon cancer	0.000173	0.00185	CcSEcCtD
Pazopanib—Alopecia—Vincristine—colon cancer	0.00017	0.00181	CcSEcCtD
Pazopanib—Angiopathy—Irinotecan—colon cancer	0.00017	0.00181	CcSEcCtD
Pazopanib—Blood creatinine increased—Capecitabine—colon cancer	0.000169	0.00181	CcSEcCtD
Pazopanib—CYP2C8—renal system—colon cancer	0.000169	0.00199	CbGeAlD
Pazopanib—Mediastinal disorder—Irinotecan—colon cancer	0.000169	0.0018	CcSEcCtD
Pazopanib—Dehydration—Capecitabine—colon cancer	0.000168	0.0018	CcSEcCtD
Pazopanib—Mental disorder—Vincristine—colon cancer	0.000168	0.0018	CcSEcCtD
Pazopanib—Chills—Irinotecan—colon cancer	0.000168	0.00179	CcSEcCtD
Pazopanib—Mouth ulceration—Methotrexate—colon cancer	0.000168	0.00179	CcSEcCtD
Pazopanib—Liver function test abnormal—Capecitabine—colon cancer	0.000167	0.00179	CcSEcCtD
Pazopanib—Dry skin—Capecitabine—colon cancer	0.000166	0.00177	CcSEcCtD
Pazopanib—Alopecia—Irinotecan—colon cancer	0.000165	0.00177	CcSEcCtD
Pazopanib—Abdominal pain upper—Capecitabine—colon cancer	0.000165	0.00177	CcSEcCtD
Pazopanib—Breast disorder—Capecitabine—colon cancer	0.000163	0.00175	CcSEcCtD
Pazopanib—Aspartate aminotransferase increased—Capecitabine—colon cancer	0.000163	0.00174	CcSEcCtD
Pazopanib—Nasopharyngitis—Capecitabine—colon cancer	0.000162	0.00173	CcSEcCtD
Pazopanib—Flatulence—Irinotecan—colon cancer	0.00016	0.00172	CcSEcCtD
Pazopanib—Alanine aminotransferase increased—Capecitabine—colon cancer	0.00016	0.00171	CcSEcCtD
Pazopanib—KDR—lymph node—colon cancer	0.000158	0.00186	CbGeAlD
Pazopanib—MAP2K5—lymph node—colon cancer	0.000158	0.00186	CbGeAlD
Pazopanib—Alopecia—Fluorouracil—colon cancer	0.000158	0.00169	CcSEcCtD
Pazopanib—CYP1A2—renal system—colon cancer	0.000158	0.00186	CbGeAlD
Pazopanib—Abdominal distension—Capecitabine—colon cancer	0.000157	0.00168	CcSEcCtD
Pazopanib—Muscle spasms—Irinotecan—colon cancer	0.000156	0.00167	CcSEcCtD
Pazopanib—Erythema—Fluorouracil—colon cancer	0.000156	0.00167	CcSEcCtD
Pazopanib—Anaemia—Vincristine—colon cancer	0.000154	0.00165	CcSEcCtD
Pazopanib—CSF1R—lymph node—colon cancer	0.000154	0.00182	CbGeAlD
Pazopanib—Anaemia—Irinotecan—colon cancer	0.00015	0.00161	CcSEcCtD
Pazopanib—Hepatic failure—Methotrexate—colon cancer	0.00015	0.0016	CcSEcCtD
Pazopanib—Leukopenia—Vincristine—colon cancer	0.00015	0.0016	CcSEcCtD
Pazopanib—Vision blurred—Fluorouracil—colon cancer	0.000147	0.00157	CcSEcCtD
Pazopanib—Neutropenia—Capecitabine—colon cancer	0.000146	0.00156	CcSEcCtD
Pazopanib—Syncope—Irinotecan—colon cancer	0.000146	0.00156	CcSEcCtD
Pazopanib—Leukopenia—Irinotecan—colon cancer	0.000146	0.00156	CcSEcCtD
Pazopanib—Hypertension—Vincristine—colon cancer	0.000144	0.00154	CcSEcCtD
Pazopanib—Anaemia—Fluorouracil—colon cancer	0.000144	0.00154	CcSEcCtD
Pazopanib—Loss of consciousness—Irinotecan—colon cancer	0.000143	0.00153	CcSEcCtD
Pazopanib—Photosensitivity reaction—Capecitabine—colon cancer	0.000143	0.00153	CcSEcCtD
Pazopanib—Myalgia—Vincristine—colon cancer	0.000142	0.00152	CcSEcCtD
Pazopanib—Cough—Irinotecan—colon cancer	0.000142	0.00152	CcSEcCtD
Pazopanib—Weight decreased—Capecitabine—colon cancer	0.000141	0.00151	CcSEcCtD
Pazopanib—Hypertension—Irinotecan—colon cancer	0.000141	0.0015	CcSEcCtD
Pazopanib—KIT—lymph node—colon cancer	0.00014	0.00165	CbGeAlD
Pazopanib—Leukopenia—Fluorouracil—colon cancer	0.00014	0.00149	CcSEcCtD
Pazopanib—Infestation NOS—Capecitabine—colon cancer	0.000139	0.00149	CcSEcCtD
Pazopanib—Infestation—Capecitabine—colon cancer	0.000139	0.00149	CcSEcCtD
Pazopanib—Acute coronary syndrome—Capecitabine—colon cancer	0.000137	0.00147	CcSEcCtD
Pazopanib—Cerebrovascular accident—Methotrexate—colon cancer	0.000137	0.00147	CcSEcCtD
Pazopanib—Lethargy—Methotrexate—colon cancer	0.000137	0.00147	CcSEcCtD
Pazopanib—PDGFRB—lymph node—colon cancer	0.000137	0.00161	CbGeAlD
Pazopanib—Myocardial infarction—Capecitabine—colon cancer	0.000137	0.00146	CcSEcCtD
Pazopanib—Oedema—Vincristine—colon cancer	0.000136	0.00146	CcSEcCtD
Pazopanib—Stomatitis—Capecitabine—colon cancer	0.000136	0.00145	CcSEcCtD
Pazopanib—Jaundice—Capecitabine—colon cancer	0.000136	0.00145	CcSEcCtD
Pazopanib—Infection—Vincristine—colon cancer	0.000136	0.00145	CcSEcCtD
Pazopanib—Nervous system disorder—Vincristine—colon cancer	0.000134	0.00143	CcSEcCtD
Pazopanib—Thrombocytopenia—Vincristine—colon cancer	0.000134	0.00143	CcSEcCtD
Pazopanib—Haematuria—Capecitabine—colon cancer	0.000133	0.00142	CcSEcCtD
Pazopanib—Oedema—Irinotecan—colon cancer	0.000133	0.00142	CcSEcCtD
Pazopanib—Myalgia—Fluorouracil—colon cancer	0.000133	0.00142	CcSEcCtD
Pazopanib—Chest pain—Fluorouracil—colon cancer	0.000133	0.00142	CcSEcCtD
Pazopanib—Infection—Irinotecan—colon cancer	0.000132	0.00141	CcSEcCtD
Pazopanib—Hyperhidrosis—Vincristine—colon cancer	0.000132	0.00141	CcSEcCtD
Pazopanib—Hepatobiliary disease—Capecitabine—colon cancer	0.000132	0.00141	CcSEcCtD
Pazopanib—Epistaxis—Capecitabine—colon cancer	0.000131	0.00141	CcSEcCtD
Pazopanib—Shock—Irinotecan—colon cancer	0.000131	0.0014	CcSEcCtD
Pazopanib—Nervous system disorder—Irinotecan—colon cancer	0.00013	0.00139	CcSEcCtD
Pazopanib—Thrombocytopenia—Irinotecan—colon cancer	0.00013	0.00139	CcSEcCtD
Pazopanib—Anorexia—Vincristine—colon cancer	0.00013	0.00139	CcSEcCtD
Pazopanib—CYP1A2—digestive system—colon cancer	0.00013	0.00153	CbGeAlD
Pazopanib—Hyperhidrosis—Irinotecan—colon cancer	0.000128	0.00137	CcSEcCtD
Pazopanib—Bradycardia—Capecitabine—colon cancer	0.000127	0.00136	CcSEcCtD
Pazopanib—Oedema—Fluorouracil—colon cancer	0.000127	0.00136	CcSEcCtD
Pazopanib—Anorexia—Irinotecan—colon cancer	0.000127	0.00135	CcSEcCtD
Pazopanib—Infection—Fluorouracil—colon cancer	0.000126	0.00135	CcSEcCtD
Pazopanib—Haemoglobin—Capecitabine—colon cancer	0.000126	0.00135	CcSEcCtD
Pazopanib—Haemorrhage—Capecitabine—colon cancer	0.000125	0.00134	CcSEcCtD
Pazopanib—Nervous system disorder—Fluorouracil—colon cancer	0.000125	0.00133	CcSEcCtD
Pazopanib—Thrombocytopenia—Fluorouracil—colon cancer	0.000125	0.00133	CcSEcCtD
Pazopanib—Hypoaesthesia—Capecitabine—colon cancer	0.000125	0.00133	CcSEcCtD
Pazopanib—Liver function test abnormal—Methotrexate—colon cancer	0.000124	0.00133	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Vincristine—colon cancer	0.000124	0.00133	CcSEcCtD
Pazopanib—ABCG2—bone marrow—colon cancer	0.000124	0.00146	CbGeAlD
Pazopanib—Urinary tract disorder—Capecitabine—colon cancer	0.000124	0.00132	CcSEcCtD
Pazopanib—Insomnia—Vincristine—colon cancer	0.000123	0.00132	CcSEcCtD
Pazopanib—Oedema peripheral—Capecitabine—colon cancer	0.000123	0.00132	CcSEcCtD
Pazopanib—Connective tissue disorder—Capecitabine—colon cancer	0.000123	0.00132	CcSEcCtD
Pazopanib—Urethral disorder—Capecitabine—colon cancer	0.000123	0.00131	CcSEcCtD
Pazopanib—Paraesthesia—Vincristine—colon cancer	0.000122	0.00131	CcSEcCtD
Pazopanib—CYP2C8—vagina—colon cancer	0.000122	0.00144	CbGeAlD
Pazopanib—Breast disorder—Methotrexate—colon cancer	0.000122	0.0013	CcSEcCtD
Pazopanib—Anorexia—Fluorouracil—colon cancer	0.000121	0.0013	CcSEcCtD
Pazopanib—Insomnia—Irinotecan—colon cancer	0.00012	0.00129	CcSEcCtD
Pazopanib—Paraesthesia—Irinotecan—colon cancer	0.000119	0.00128	CcSEcCtD
Pazopanib—ABCG2—vagina—colon cancer	0.000119	0.0014	CbGeAlD
Pazopanib—Decreased appetite—Vincristine—colon cancer	0.000119	0.00127	CcSEcCtD
Pazopanib—Dyspnoea—Irinotecan—colon cancer	0.000118	0.00127	CcSEcCtD
Pazopanib—Somnolence—Irinotecan—colon cancer	0.000118	0.00126	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Vincristine—colon cancer	0.000118	0.00126	CcSEcCtD
Pazopanib—Fatigue—Vincristine—colon cancer	0.000118	0.00126	CcSEcCtD
Pazopanib—Eye disorder—Capecitabine—colon cancer	0.000117	0.00125	CcSEcCtD
Pazopanib—Dyspepsia—Irinotecan—colon cancer	0.000117	0.00125	CcSEcCtD
Pazopanib—Pain—Vincristine—colon cancer	0.000117	0.00125	CcSEcCtD
Pazopanib—Cardiac disorder—Capecitabine—colon cancer	0.000116	0.00124	CcSEcCtD
Pazopanib—Flushing—Capecitabine—colon cancer	0.000116	0.00124	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000116	0.00124	CcSEcCtD
Pazopanib—Decreased appetite—Irinotecan—colon cancer	0.000115	0.00124	CcSEcCtD
Pazopanib—Insomnia—Fluorouracil—colon cancer	0.000115	0.00123	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Irinotecan—colon cancer	0.000115	0.00123	CcSEcCtD
Pazopanib—Fatigue—Irinotecan—colon cancer	0.000115	0.00122	CcSEcCtD
Pazopanib—CYP3A4—renal system—colon cancer	0.000114	0.00135	CbGeAlD
Pazopanib—Paraesthesia—Fluorouracil—colon cancer	0.000114	0.00122	CcSEcCtD
Pazopanib—Pancreatitis—Methotrexate—colon cancer	0.000114	0.00122	CcSEcCtD
Pazopanib—Pain—Irinotecan—colon cancer	0.000114	0.00121	CcSEcCtD
Pazopanib—Angiopathy—Capecitabine—colon cancer	0.000114	0.00121	CcSEcCtD
Pazopanib—Dyspnoea—Fluorouracil—colon cancer	0.000113	0.00121	CcSEcCtD
Pazopanib—Somnolence—Fluorouracil—colon cancer	0.000113	0.00121	CcSEcCtD
Pazopanib—Mediastinal disorder—Capecitabine—colon cancer	0.000113	0.00121	CcSEcCtD
Pazopanib—CYP2D6—renal system—colon cancer	0.000113	0.00132	CbGeAlD
Pazopanib—Chills—Capecitabine—colon cancer	0.000112	0.0012	CcSEcCtD
Pazopanib—Dyspepsia—Fluorouracil—colon cancer	0.000112	0.0012	CcSEcCtD
Pazopanib—Gastrointestinal pain—Vincristine—colon cancer	0.000112	0.00119	CcSEcCtD
Pazopanib—Decreased appetite—Fluorouracil—colon cancer	0.000111	0.00118	CcSEcCtD
Pazopanib—Alopecia—Capecitabine—colon cancer	0.000111	0.00118	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Fluorouracil—colon cancer	0.00011	0.00117	CcSEcCtD
Pazopanib—Mental disorder—Capecitabine—colon cancer	0.00011	0.00117	CcSEcCtD
Pazopanib—Malnutrition—Capecitabine—colon cancer	0.000109	0.00117	CcSEcCtD
Pazopanib—Erythema—Capecitabine—colon cancer	0.000109	0.00117	CcSEcCtD
Pazopanib—Neutropenia—Methotrexate—colon cancer	0.000109	0.00116	CcSEcCtD
Pazopanib—Pain—Fluorouracil—colon cancer	0.000109	0.00116	CcSEcCtD
Pazopanib—Gastrointestinal pain—Irinotecan—colon cancer	0.000109	0.00116	CcSEcCtD
Pazopanib—Abdominal pain—Vincristine—colon cancer	0.000108	0.00115	CcSEcCtD
Pazopanib—Flatulence—Capecitabine—colon cancer	0.000107	0.00115	CcSEcCtD
Pazopanib—ABCB1—embryo—colon cancer	0.000107	0.00126	CbGeAlD
Pazopanib—Dysgeusia—Capecitabine—colon cancer	0.000107	0.00114	CcSEcCtD
Pazopanib—Photosensitivity reaction—Methotrexate—colon cancer	0.000106	0.00114	CcSEcCtD
Pazopanib—Abdominal pain—Irinotecan—colon cancer	0.000105	0.00112	CcSEcCtD
Pazopanib—Muscle spasms—Capecitabine—colon cancer	0.000105	0.00112	CcSEcCtD
Pazopanib—Infestation—Methotrexate—colon cancer	0.000104	0.00111	CcSEcCtD
Pazopanib—Infestation NOS—Methotrexate—colon cancer	0.000104	0.00111	CcSEcCtD
Pazopanib—CYP2C8—liver—colon cancer	0.000103	0.00121	CbGeAlD
Pazopanib—Vision blurred—Capecitabine—colon cancer	0.000103	0.0011	CcSEcCtD
Pazopanib—Stomatitis—Methotrexate—colon cancer	0.000101	0.00108	CcSEcCtD
Pazopanib—Anaemia—Capecitabine—colon cancer	0.000101	0.00108	CcSEcCtD
Pazopanib—ABCG2—liver—colon cancer	0.0001	0.00118	CbGeAlD
Pazopanib—Haematuria—Methotrexate—colon cancer	9.89e-05	0.00106	CcSEcCtD
Pazopanib—Hepatobiliary disease—Methotrexate—colon cancer	9.81e-05	0.00105	CcSEcCtD
Pazopanib—Epistaxis—Methotrexate—colon cancer	9.79e-05	0.00105	CcSEcCtD
Pazopanib—Asthenia—Vincristine—colon cancer	9.79e-05	0.00105	CcSEcCtD
Pazopanib—Syncope—Capecitabine—colon cancer	9.77e-05	0.00104	CcSEcCtD
Pazopanib—Leukopenia—Capecitabine—colon cancer	9.75e-05	0.00104	CcSEcCtD
Pazopanib—CYP1A2—liver—colon cancer	9.67e-05	0.00114	CbGeAlD
Pazopanib—Loss of consciousness—Capecitabine—colon cancer	9.57e-05	0.00102	CcSEcCtD
Pazopanib—Asthenia—Irinotecan—colon cancer	9.53e-05	0.00102	CcSEcCtD
Pazopanib—Cough—Capecitabine—colon cancer	9.51e-05	0.00102	CcSEcCtD
Pazopanib—Hypertension—Capecitabine—colon cancer	9.4e-05	0.00101	CcSEcCtD
Pazopanib—CYP3A4—digestive system—colon cancer	9.39e-05	0.0011	CbGeAlD
Pazopanib—Haemoglobin—Methotrexate—colon cancer	9.36e-05	0.001	CcSEcCtD
Pazopanib—Diarrhoea—Vincristine—colon cancer	9.33e-05	0.000998	CcSEcCtD
Pazopanib—Haemorrhage—Methotrexate—colon cancer	9.32e-05	0.000996	CcSEcCtD
Pazopanib—Chest pain—Capecitabine—colon cancer	9.27e-05	0.000992	CcSEcCtD
Pazopanib—Myalgia—Capecitabine—colon cancer	9.27e-05	0.000992	CcSEcCtD
Pazopanib—Arthralgia—Capecitabine—colon cancer	9.27e-05	0.000992	CcSEcCtD
Pazopanib—CYP2D6—digestive system—colon cancer	9.24e-05	0.00109	CbGeAlD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	9.21e-05	0.000985	CcSEcCtD
Pazopanib—Urinary tract disorder—Methotrexate—colon cancer	9.2e-05	0.000984	CcSEcCtD
Pazopanib—Urethral disorder—Methotrexate—colon cancer	9.13e-05	0.000977	CcSEcCtD
Pazopanib—Diarrhoea—Irinotecan—colon cancer	9.09e-05	0.000972	CcSEcCtD
Pazopanib—Dry mouth—Capecitabine—colon cancer	9.07e-05	0.00097	CcSEcCtD
Pazopanib—Dizziness—Vincristine—colon cancer	9.02e-05	0.000965	CcSEcCtD
Pazopanib—Pruritus—Fluorouracil—colon cancer	9e-05	0.000963	CcSEcCtD
Pazopanib—Oedema—Capecitabine—colon cancer	8.89e-05	0.000951	CcSEcCtD
Pazopanib—Infection—Capecitabine—colon cancer	8.83e-05	0.000945	CcSEcCtD
Pazopanib—Dizziness—Irinotecan—colon cancer	8.78e-05	0.00094	CcSEcCtD
Pazopanib—Shock—Capecitabine—colon cancer	8.75e-05	0.000936	CcSEcCtD
Pazopanib—ABCB1—epithelium—colon cancer	8.74e-05	0.00103	CbGeAlD
Pazopanib—Nervous system disorder—Capecitabine—colon cancer	8.72e-05	0.000933	CcSEcCtD
Pazopanib—Eye disorder—Methotrexate—colon cancer	8.71e-05	0.000931	CcSEcCtD
Pazopanib—Diarrhoea—Fluorouracil—colon cancer	8.7e-05	0.000931	CcSEcCtD
Pazopanib—Thrombocytopenia—Capecitabine—colon cancer	8.7e-05	0.000931	CcSEcCtD
Pazopanib—Vomiting—Vincristine—colon cancer	8.67e-05	0.000928	CcSEcCtD
Pazopanib—Cardiac disorder—Methotrexate—colon cancer	8.65e-05	0.000925	CcSEcCtD
Pazopanib—Skin disorder—Capecitabine—colon cancer	8.64e-05	0.000924	CcSEcCtD
Pazopanib—Rash—Vincristine—colon cancer	8.6e-05	0.00092	CcSEcCtD
Pazopanib—Hyperhidrosis—Capecitabine—colon cancer	8.59e-05	0.000919	CcSEcCtD
Pazopanib—Dermatitis—Vincristine—colon cancer	8.59e-05	0.000919	CcSEcCtD
Pazopanib—Headache—Vincristine—colon cancer	8.54e-05	0.000914	CcSEcCtD
Pazopanib—Anorexia—Capecitabine—colon cancer	8.47e-05	0.000906	CcSEcCtD
Pazopanib—Angiopathy—Methotrexate—colon cancer	8.45e-05	0.000904	CcSEcCtD
Pazopanib—Vomiting—Irinotecan—colon cancer	8.45e-05	0.000903	CcSEcCtD
Pazopanib—Dizziness—Fluorouracil—colon cancer	8.41e-05	0.0009	CcSEcCtD
Pazopanib—Mediastinal disorder—Methotrexate—colon cancer	8.4e-05	0.000898	CcSEcCtD
Pazopanib—Rash—Irinotecan—colon cancer	8.38e-05	0.000896	CcSEcCtD
Pazopanib—Dermatitis—Irinotecan—colon cancer	8.37e-05	0.000895	CcSEcCtD
Pazopanib—Chills—Methotrexate—colon cancer	8.36e-05	0.000894	CcSEcCtD
Pazopanib—Headache—Irinotecan—colon cancer	8.32e-05	0.00089	CcSEcCtD
Pazopanib—Alopecia—Methotrexate—colon cancer	8.23e-05	0.00088	CcSEcCtD
Pazopanib—Mental disorder—Methotrexate—colon cancer	8.16e-05	0.000873	CcSEcCtD
Pazopanib—Malnutrition—Methotrexate—colon cancer	8.11e-05	0.000867	CcSEcCtD
Pazopanib—Erythema—Methotrexate—colon cancer	8.11e-05	0.000867	CcSEcCtD
Pazopanib—ABCB1—renal system—colon cancer	8.1e-05	0.000953	CbGeAlD
Pazopanib—Nausea—Vincristine—colon cancer	8.1e-05	0.000867	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Capecitabine—colon cancer	8.1e-05	0.000866	CcSEcCtD
Pazopanib—Vomiting—Fluorouracil—colon cancer	8.09e-05	0.000865	CcSEcCtD
Pazopanib—Insomnia—Capecitabine—colon cancer	8.04e-05	0.00086	CcSEcCtD
Pazopanib—Rash—Fluorouracil—colon cancer	8.02e-05	0.000858	CcSEcCtD
Pazopanib—Dermatitis—Fluorouracil—colon cancer	8.01e-05	0.000857	CcSEcCtD
Pazopanib—Paraesthesia—Capecitabine—colon cancer	7.98e-05	0.000854	CcSEcCtD
Pazopanib—Headache—Fluorouracil—colon cancer	7.97e-05	0.000852	CcSEcCtD
Pazopanib—Dysgeusia—Methotrexate—colon cancer	7.94e-05	0.000849	CcSEcCtD
Pazopanib—Dyspnoea—Capecitabine—colon cancer	7.93e-05	0.000848	CcSEcCtD
Pazopanib—Nausea—Irinotecan—colon cancer	7.89e-05	0.000844	CcSEcCtD
Pazopanib—Dyspepsia—Capecitabine—colon cancer	7.83e-05	0.000837	CcSEcCtD
Pazopanib—Decreased appetite—Capecitabine—colon cancer	7.73e-05	0.000827	CcSEcCtD
Pazopanib—ABCG2—lymph node—colon cancer	7.7e-05	0.000906	CbGeAlD
Pazopanib—Gastrointestinal disorder—Capecitabine—colon cancer	7.68e-05	0.000821	CcSEcCtD
Pazopanib—Fatigue—Capecitabine—colon cancer	7.67e-05	0.00082	CcSEcCtD
Pazopanib—Vision blurred—Methotrexate—colon cancer	7.64e-05	0.000817	CcSEcCtD
Pazopanib—Pain—Capecitabine—colon cancer	7.6e-05	0.000813	CcSEcCtD
Pazopanib—Nausea—Fluorouracil—colon cancer	7.56e-05	0.000808	CcSEcCtD
Pazopanib—Anaemia—Methotrexate—colon cancer	7.5e-05	0.000802	CcSEcCtD
Pazopanib—Gastrointestinal pain—Capecitabine—colon cancer	7.27e-05	0.000778	CcSEcCtD
Pazopanib—Leukopenia—Methotrexate—colon cancer	7.26e-05	0.000776	CcSEcCtD
Pazopanib—Cough—Methotrexate—colon cancer	7.08e-05	0.000757	CcSEcCtD
Pazopanib—Abdominal pain—Capecitabine—colon cancer	7.03e-05	0.000752	CcSEcCtD
Pazopanib—CYP3A4—liver—colon cancer	7e-05	0.000823	CbGeAlD
Pazopanib—Chest pain—Methotrexate—colon cancer	6.9e-05	0.000738	CcSEcCtD
Pazopanib—Myalgia—Methotrexate—colon cancer	6.9e-05	0.000738	CcSEcCtD
Pazopanib—Arthralgia—Methotrexate—colon cancer	6.9e-05	0.000738	CcSEcCtD
Pazopanib—CYP2D6—liver—colon cancer	6.88e-05	0.00081	CbGeAlD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	6.86e-05	0.000733	CcSEcCtD
Pazopanib—ABCB1—lymphoid tissue—colon cancer	6.73e-05	0.000791	CbGeAlD
Pazopanib—ABCB1—digestive system—colon cancer	6.65e-05	0.000782	CbGeAlD
Pazopanib—Infection—Methotrexate—colon cancer	6.58e-05	0.000703	CcSEcCtD
Pazopanib—Nervous system disorder—Methotrexate—colon cancer	6.49e-05	0.000694	CcSEcCtD
Pazopanib—Thrombocytopenia—Methotrexate—colon cancer	6.48e-05	0.000693	CcSEcCtD
Pazopanib—Skin disorder—Methotrexate—colon cancer	6.43e-05	0.000688	CcSEcCtD
Pazopanib—Hyperhidrosis—Methotrexate—colon cancer	6.4e-05	0.000684	CcSEcCtD
Pazopanib—Asthenia—Capecitabine—colon cancer	6.38e-05	0.000682	CcSEcCtD
Pazopanib—Anorexia—Methotrexate—colon cancer	6.31e-05	0.000675	CcSEcCtD
Pazopanib—Pruritus—Capecitabine—colon cancer	6.29e-05	0.000673	CcSEcCtD
Pazopanib—ABCB1—bone marrow—colon cancer	6.13e-05	0.000721	CbGeAlD
Pazopanib—Diarrhoea—Capecitabine—colon cancer	6.08e-05	0.000651	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Methotrexate—colon cancer	6.03e-05	0.000645	CcSEcCtD
Pazopanib—Insomnia—Methotrexate—colon cancer	5.99e-05	0.00064	CcSEcCtD
Pazopanib—Paraesthesia—Methotrexate—colon cancer	5.94e-05	0.000636	CcSEcCtD
Pazopanib—Dyspnoea—Methotrexate—colon cancer	5.9e-05	0.000631	CcSEcCtD
Pazopanib—Somnolence—Methotrexate—colon cancer	5.88e-05	0.000629	CcSEcCtD
Pazopanib—Dizziness—Capecitabine—colon cancer	5.88e-05	0.000629	CcSEcCtD
Pazopanib—ABCB1—vagina—colon cancer	5.87e-05	0.00069	CbGeAlD
Pazopanib—Dyspepsia—Methotrexate—colon cancer	5.83e-05	0.000623	CcSEcCtD
Pazopanib—Decreased appetite—Methotrexate—colon cancer	5.75e-05	0.000615	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Methotrexate—colon cancer	5.71e-05	0.000611	CcSEcCtD
Pazopanib—Fatigue—Methotrexate—colon cancer	5.71e-05	0.00061	CcSEcCtD
Pazopanib—Pain—Methotrexate—colon cancer	5.66e-05	0.000605	CcSEcCtD
Pazopanib—Vomiting—Capecitabine—colon cancer	5.65e-05	0.000605	CcSEcCtD
Pazopanib—Rash—Capecitabine—colon cancer	5.61e-05	0.0006	CcSEcCtD
Pazopanib—Dermatitis—Capecitabine—colon cancer	5.6e-05	0.000599	CcSEcCtD
Pazopanib—Headache—Capecitabine—colon cancer	5.57e-05	0.000596	CcSEcCtD
Pazopanib—Gastrointestinal pain—Methotrexate—colon cancer	5.41e-05	0.000579	CcSEcCtD
Pazopanib—Nausea—Capecitabine—colon cancer	5.28e-05	0.000565	CcSEcCtD
Pazopanib—Abdominal pain—Methotrexate—colon cancer	5.23e-05	0.00056	CcSEcCtD
Pazopanib—ABCB1—liver—colon cancer	4.95e-05	0.000582	CbGeAlD
Pazopanib—Asthenia—Methotrexate—colon cancer	4.75e-05	0.000508	CcSEcCtD
Pazopanib—Pruritus—Methotrexate—colon cancer	4.68e-05	0.000501	CcSEcCtD
Pazopanib—Diarrhoea—Methotrexate—colon cancer	4.53e-05	0.000484	CcSEcCtD
Pazopanib—Dizziness—Methotrexate—colon cancer	4.38e-05	0.000468	CcSEcCtD
Pazopanib—Vomiting—Methotrexate—colon cancer	4.21e-05	0.00045	CcSEcCtD
Pazopanib—Rash—Methotrexate—colon cancer	4.17e-05	0.000446	CcSEcCtD
Pazopanib—Dermatitis—Methotrexate—colon cancer	4.17e-05	0.000446	CcSEcCtD
Pazopanib—Headache—Methotrexate—colon cancer	4.15e-05	0.000443	CcSEcCtD
Pazopanib—Nausea—Methotrexate—colon cancer	3.93e-05	0.00042	CcSEcCtD
Pazopanib—ABCB1—lymph node—colon cancer	3.8e-05	0.000447	CbGeAlD
Pazopanib—KIT—Signaling Pathways—CASP3—colon cancer	3.02e-06	2.53e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—CDKN1A—colon cancer	3.01e-06	2.52e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CCND1—colon cancer	2.99e-06	2.51e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—colon cancer	2.99e-06	2.5e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—EGFR—colon cancer	2.98e-06	2.49e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—EGFR—colon cancer	2.97e-06	2.49e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—AKT1—colon cancer	2.97e-06	2.49e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CTNNB1—colon cancer	2.96e-06	2.48e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—PIK3CA—colon cancer	2.96e-06	2.48e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—KRAS—colon cancer	2.95e-06	2.47e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—KRAS—colon cancer	2.94e-06	2.47e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CCND1—colon cancer	2.94e-06	2.46e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—PIK3CA—colon cancer	2.94e-06	2.46e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—APC—colon cancer	2.93e-06	2.45e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—PIK3CA—colon cancer	2.93e-06	2.45e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—ABCB1—colon cancer	2.92e-06	2.45e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—HRAS—colon cancer	2.91e-06	2.44e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CTNNB1—colon cancer	2.91e-06	2.44e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—PIK3CA—colon cancer	2.91e-06	2.44e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—MYC—colon cancer	2.9e-06	2.43e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CDKN1A—colon cancer	2.89e-06	2.42e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—TGFB1—colon cancer	2.89e-06	2.42e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—KRAS—colon cancer	2.88e-06	2.41e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—KRAS—colon cancer	2.87e-06	2.41e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—AKT1—colon cancer	2.87e-06	2.4e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—TYMS—colon cancer	2.87e-06	2.4e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—MYC—colon cancer	2.87e-06	2.4e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—TP53—colon cancer	2.86e-06	2.4e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CASP3—colon cancer	2.86e-06	2.4e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—TGFB1—colon cancer	2.86e-06	2.4e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—HRAS—colon cancer	2.86e-06	2.4e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—EP300—colon cancer	2.86e-06	2.4e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CASP3—colon cancer	2.86e-06	2.39e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—PIK3CA—colon cancer	2.86e-06	2.39e-05	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—AKT1—colon cancer	2.85e-06	2.39e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—CTNNB1—colon cancer	2.84e-06	2.38e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CDKN1A—colon cancer	2.84e-06	2.38e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—EGFR—colon cancer	2.83e-06	2.38e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—KRAS—colon cancer	2.81e-06	2.36e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—KRAS—colon cancer	2.81e-06	2.35e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—EGFR—colon cancer	2.81e-06	2.35e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CCND1—colon cancer	2.79e-06	2.34e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PTGS2—colon cancer	2.78e-06	2.33e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—SRC—colon cancer	2.78e-06	2.33e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CCND1—colon cancer	2.78e-06	2.33e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—CDKN1A—colon cancer	2.78e-06	2.33e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CTNNB1—colon cancer	2.76e-06	2.31e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—BRAF—colon cancer	2.75e-06	2.31e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CTNNB1—colon cancer	2.75e-06	2.31e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—EP300—colon cancer	2.75e-06	2.31e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—HRAS—colon cancer	2.74e-06	2.29e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—HRAS—colon cancer	2.72e-06	2.28e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—PIK3CA—colon cancer	2.71e-06	2.27e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—HRAS—colon cancer	2.71e-06	2.27e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—EP300—colon cancer	2.7e-06	2.26e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—PIK3CA—colon cancer	2.7e-06	2.26e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CDKN1A—colon cancer	2.7e-06	2.26e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—HRAS—colon cancer	2.69e-06	2.25e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CDKN1A—colon cancer	2.69e-06	2.25e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—KRAS—colon cancer	2.68e-06	2.24e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—NRAS—colon cancer	2.68e-06	2.24e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—SRC—colon cancer	2.68e-06	2.24e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—KRAS—colon cancer	2.65e-06	2.22e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—PIK3CA—colon cancer	2.65e-06	2.22e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—HRAS—colon cancer	2.64e-06	2.21e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—EP300—colon cancer	2.64e-06	2.21e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—PIK3CA—colon cancer	2.64e-06	2.21e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—SRC—colon cancer	2.63e-06	2.2e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—VEGFA—colon cancer	2.61e-06	2.18e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—PIK3CA—colon cancer	2.58e-06	2.16e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—PIK3CA—colon cancer	2.58e-06	2.16e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PTGS2—colon cancer	2.58e-06	2.16e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—NRAS—colon cancer	2.57e-06	2.16e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CASP3—colon cancer	2.57e-06	2.16e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—AKT1—colon cancer	2.57e-06	2.16e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—SRC—colon cancer	2.57e-06	2.15e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—EP300—colon cancer	2.57e-06	2.15e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—VEGFA—colon cancer	2.56e-06	2.15e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—TP53—colon cancer	2.56e-06	2.15e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—EP300—colon cancer	2.56e-06	2.14e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—NRAS—colon cancer	2.53e-06	2.12e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—AKT1—colon cancer	2.53e-06	2.12e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—EP300—colon cancer	2.53e-06	2.12e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CASP3—colon cancer	2.52e-06	2.11e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—HRAS—colon cancer	2.51e-06	2.1e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CCND1—colon cancer	2.5e-06	2.1e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—HRAS—colon cancer	2.5e-06	2.1e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—TYMS—colon cancer	2.5e-06	2.09e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	2.5e-06	2.09e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—TP53—colon cancer	2.49e-06	2.09e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—SRC—colon cancer	2.49e-06	2.09e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—SRC—colon cancer	2.49e-06	2.08e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CTNNB1—colon cancer	2.48e-06	2.08e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—NRAS—colon cancer	2.47e-06	2.07e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—PIK3CA—colon cancer	2.46e-06	2.06e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CCND1—colon cancer	2.45e-06	2.05e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—HRAS—colon cancer	2.45e-06	2.05e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—HRAS—colon cancer	2.44e-06	2.04e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—EGFR—colon cancer	2.44e-06	2.04e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—PIK3CA—colon cancer	2.44e-06	2.04e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—VEGFA—colon cancer	2.43e-06	2.04e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CTNNB1—colon cancer	2.43e-06	2.03e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—VEGFA—colon cancer	2.42e-06	2.03e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CDKN1A—colon cancer	2.42e-06	2.03e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—AKT1—colon cancer	2.42e-06	2.03e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—NRAS—colon cancer	2.4e-06	2.01e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ABCB1—colon cancer	2.4e-06	2.01e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MYC—colon cancer	2.4e-06	2.01e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—AKT1—colon cancer	2.4e-06	2.01e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—NRAS—colon cancer	2.39e-06	2.01e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TGFB1—colon cancer	2.39e-06	2e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—AKT1—colon cancer	2.39e-06	2e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—HRAS—colon cancer	2.39e-06	2e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—HRAS—colon cancer	2.39e-06	2e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—TP53—colon cancer	2.38e-06	1.99e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—AKT1—colon cancer	2.38e-06	1.99e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CDKN1A—colon cancer	2.37e-06	1.99e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—TYMS—colon cancer	2.36e-06	1.97e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MYC—colon cancer	2.36e-06	1.97e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TGFB1—colon cancer	2.35e-06	1.97e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—EGFR—colon cancer	2.35e-06	1.97e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—AKT1—colon cancer	2.33e-06	1.95e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—EP300—colon cancer	2.31e-06	1.94e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—EP300—colon cancer	2.31e-06	1.93e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—EGFR—colon cancer	2.3e-06	1.93e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—KRAS—colon cancer	2.3e-06	1.93e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—MYC—colon cancer	2.3e-06	1.93e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—TGFB1—colon cancer	2.3e-06	1.92e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—HRAS—colon cancer	2.28e-06	1.91e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—EP300—colon cancer	2.26e-06	1.89e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—HRAS—colon cancer	2.25e-06	1.89e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—EGFR—colon cancer	2.25e-06	1.89e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—SRC—colon cancer	2.24e-06	1.88e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MYC—colon cancer	2.24e-06	1.87e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TGFB1—colon cancer	2.23e-06	1.87e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MYC—colon cancer	2.23e-06	1.87e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TGFB1—colon cancer	2.22e-06	1.86e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—KRAS—colon cancer	2.22e-06	1.86e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—AKT1—colon cancer	2.21e-06	1.85e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	2.21e-06	1.85e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—AKT1—colon cancer	2.21e-06	1.85e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—SRC—colon cancer	2.19e-06	1.84e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—EGFR—colon cancer	2.19e-06	1.83e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—VEGFA—colon cancer	2.18e-06	1.83e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—EGFR—colon cancer	2.18e-06	1.83e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—KRAS—colon cancer	2.18e-06	1.82e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—AKT1—colon cancer	2.16e-06	1.81e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—NRAS—colon cancer	2.16e-06	1.81e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—AKT1—colon cancer	2.15e-06	1.81e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—EP300—colon cancer	2.14e-06	1.8e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—VEGFA—colon cancer	2.14e-06	1.79e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—KRAS—colon cancer	2.13e-06	1.78e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—PIK3CA—colon cancer	2.12e-06	1.77e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—NRAS—colon cancer	2.11e-06	1.77e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—AKT1—colon cancer	2.11e-06	1.77e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—AKT1—colon cancer	2.11e-06	1.77e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—colon cancer	2.08e-06	1.74e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—KRAS—colon cancer	2.07e-06	1.73e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CASP3—colon cancer	2.06e-06	1.73e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—KRAS—colon cancer	2.06e-06	1.73e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—PIK3CA—colon cancer	2.04e-06	1.71e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PPARG—colon cancer	2.03e-06	1.7e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ABCB1—colon cancer	2.03e-06	1.7e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CCND1—colon cancer	2.01e-06	1.68e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—AKT1—colon cancer	2.01e-06	1.68e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MYC—colon cancer	2.01e-06	1.68e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TGFB1—colon cancer	2e-06	1.68e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—PIK3CA—colon cancer	2e-06	1.68e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—TYMS—colon cancer	2e-06	1.67e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CTNNB1—colon cancer	1.99e-06	1.67e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—AKT1—colon cancer	1.99e-06	1.67e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TP53—colon cancer	1.97e-06	1.65e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MYC—colon cancer	1.97e-06	1.65e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—EGFR—colon cancer	1.96e-06	1.65e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TGFB1—colon cancer	1.96e-06	1.64e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—HRAS—colon cancer	1.96e-06	1.64e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—PIK3CA—colon cancer	1.95e-06	1.64e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CDKN1A—colon cancer	1.94e-06	1.63e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TP53—colon cancer	1.93e-06	1.62e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—EGFR—colon cancer	1.92e-06	1.61e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—PIK3CA—colon cancer	1.9e-06	1.59e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—PIK3CA—colon cancer	1.89e-06	1.59e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—HRAS—colon cancer	1.88e-06	1.58e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—PIK3CA—colon cancer	1.87e-06	1.57e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—KRAS—colon cancer	1.86e-06	1.56e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—HRAS—colon cancer	1.85e-06	1.55e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—EP300—colon cancer	1.85e-06	1.55e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TP53—colon cancer	1.84e-06	1.54e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TP53—colon cancer	1.83e-06	1.53e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—KRAS—colon cancer	1.82e-06	1.52e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—HRAS—colon cancer	1.81e-06	1.51e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—SRC—colon cancer	1.8e-06	1.51e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PPARG—colon cancer	1.77e-06	1.48e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—HRAS—colon cancer	1.76e-06	1.47e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—VEGFA—colon cancer	1.75e-06	1.47e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—HRAS—colon cancer	1.75e-06	1.47e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—NRAS—colon cancer	1.73e-06	1.45e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—AKT1—colon cancer	1.73e-06	1.45e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PIK3CA—colon cancer	1.71e-06	1.43e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—PIK3CA—colon cancer	1.71e-06	1.43e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—PIK3CA—colon cancer	1.67e-06	1.4e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PPARG—colon cancer	1.67e-06	1.4e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—AKT1—colon cancer	1.66e-06	1.39e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TP53—colon cancer	1.65e-06	1.38e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—AKT1—colon cancer	1.63e-06	1.37e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TP53—colon cancer	1.62e-06	1.35e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MYC—colon cancer	1.61e-06	1.35e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TGFB1—colon cancer	1.61e-06	1.35e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PTGS2—colon cancer	1.6e-06	1.34e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—AKT1—colon cancer	1.6e-06	1.34e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PIK3CA—colon cancer	1.59e-06	1.33e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—HRAS—colon cancer	1.58e-06	1.32e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—EGFR—colon cancer	1.58e-06	1.32e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ABCB1—colon cancer	1.57e-06	1.31e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—AKT1—colon cancer	1.55e-06	1.3e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—AKT1—colon cancer	1.55e-06	1.3e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—HRAS—colon cancer	1.54e-06	1.29e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—TYMS—colon cancer	1.54e-06	1.29e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.54e-06	1.29e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—AKT1—colon cancer	1.53e-06	1.28e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—KRAS—colon cancer	1.49e-06	1.25e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PPARG—colon cancer	1.41e-06	1.18e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—AKT1—colon cancer	1.4e-06	1.17e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PTGS2—colon cancer	1.39e-06	1.17e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—AKT1—colon cancer	1.39e-06	1.17e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PIK3CA—colon cancer	1.37e-06	1.15e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—AKT1—colon cancer	1.36e-06	1.14e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—EP300—colon cancer	1.33e-06	1.11e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TP53—colon cancer	1.32e-06	1.11e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PTGS2—colon cancer	1.31e-06	1.1e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—AKT1—colon cancer	1.3e-06	1.09e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—HRAS—colon cancer	1.27e-06	1.06e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—EP300—colon cancer	1.16e-06	9.71e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—AKT1—colon cancer	1.12e-06	9.37e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PTGS2—colon cancer	1.11e-06	9.32e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—EP300—colon cancer	1.09e-06	9.15e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PPARG—colon cancer	1.09e-06	9.14e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3CA—colon cancer	9.84e-07	8.24e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—EP300—colon cancer	9.25e-07	7.75e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PTGS2—colon cancer	8.58e-07	7.19e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3CA—colon cancer	8.57e-07	7.18e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3CA—colon cancer	8.08e-07	6.77e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—AKT1—colon cancer	8.04e-07	6.73e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—EP300—colon cancer	7.14e-07	5.98e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—AKT1—colon cancer	7e-07	5.87e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3CA—colon cancer	6.84e-07	5.73e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—AKT1—colon cancer	6.6e-07	5.53e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—AKT1—colon cancer	5.59e-07	4.68e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3CA—colon cancer	5.28e-07	4.43e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—AKT1—colon cancer	4.31e-07	3.61e-06	CbGpPWpGaD
